Glenmark Pharma unveils triple FDC Zita-PioMet for Type 2 diabetes in India

This offers patients with Type 2 diabetes the convenience of once-daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks.

Published On 2022-12-23 05:45 GMT | Update On 2022-12-23 05:45 GMT

Mumbai: Glenmark Pharmaceuticals Limited, a global pharmaceutical company has launched the first triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India.Teneligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor). This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) +...

Mumbai: Glenmark Pharmaceuticals Limited, a global pharmaceutical company has launched the first triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India.

Teneligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor). This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation.

This offers patients with Type 2 diabetes the convenience of once-daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks.

On occasion of the launch, Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd., said, "Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38% compared to the global incidence of 15%. Being a leader in diabetes therapy in the country, we are proud to introduce Zita-PioMet, India's first triple fixed-dose combination for high insulin-resistant type 2 diabetes. The innovative, effective, and affordable drug will help improve the glycemic control among adult patients with high HbA1c."

According to IQVIA sales data for the 12‐month period ending November 2022, the market for oral anti‐diabetic drugs in India is estimated to be Rs. 11,877 Cr. with an annual growth of 6.3% against the corresponding period last year (MAT November 2021). As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045, 77% of which would have uncontrolled diabetes.

In 2015, Glenmark launched the DPP4 inhibitor, Teneligliptin (Zita Plus and Ziten), followed by a FDC of Teneligliptin + Metformin (Zita-Met Plus and Ziten-M). Glenmark later launched Remogliflozin (Remo and Remozen), a novel SGLT‐2 inhibitor in 2019, and subsequently, its combinations with Metformin and Vildagliptin (Remo-V, Remozen-V, Remo MV, and Remozen MV). Earlier in 2022, Glenmark also launched Sitagliptin (Sitazit) and its FDCs, followed by Lobeglitazone (LOBG) and FDCs of Teneligliptin including its combinations with Pioglitazone (Zita Pio) and Dapagliflozin (Zita-D).

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Glenmark Pharma unveils triple FDC Zita-PioMet for Type 2 diabetes in India

This offers patients with Type 2 diabetes the convenience of once-daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks.

Similar News